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ABSTRACT
Background: Parenteral nutrition is central to the care of very
immature infants. Current international recommendations favor
higher amino acid intakes and fish oil–containing lipid emulsions.
Objective: The aim of this trial was to compare 1) the effects of
high [immediate recommended daily intake (Imm-RDI)] and low
[incremental introduction of amino acids (Inc-AAs)] parenteral
amino acid delivery within 24 h of birth on body composition and
2) the effect of a multicomponent lipid emulsion containing 30%
soybean oil, 30% medium-chain triglycerides, 25% olive oil, and
15% fish oil (SMOF) with that of soybean oil (SO)-based lipid
emulsion on intrahepatocellular lipid (IHCL) content.
Design: We conducted a 2-by-2 factorial, double-blind, multicenter
randomized controlled trial.
Results: We randomly assigned 168 infants born at ,31 wk of ges-
tation. We evaluated outcomes at term in 133 infants. There were no
significant differences between Imm-RDI and Inc-AA groups for non-
adipose mass [adjusted mean difference: 1.0 g (95% CI: 2108, 111 g;
P = 0.98)] or between SMOF and SO groups for IHCL [adjusted mean
SMOF:SO ratio: 1.1 (95% CI: 0.8, 1.6; P = 0.58]. SMOF does not
affect IHCL content. There was a significant interaction (P = 0.05)
between the 2 interventions for nonadipose mass. There were no sig-
nificant interactions between group differences for either primary out-
come measure after adjusting for additional confounders. Imm-RDI
infants were more likely than Inc-AA infants to have blood urea nitro-
gen concentrations .7 mmol/L or .10 mmol/L, respectively (75%
compared with 49%, P , 0.01; 49% compared with 18%, P , 0.01).
Head circumference at term was smaller in the Imm-RDI group [mean
difference: 20.8 cm (95% CI: 21.5, 20.1 cm; P = 0.02)]. There were
no significant differences in any prespecified secondary outcomes, in-
cluding adiposity, liver function tests, incidence of conjugated hyper-
bilirubinemia, weight, length, mortality, and brain volumes.
Conclusion: Imm-RDI of parenteral amino acids does not benefit
body composition or growth to term and may be harmful. This trial
was registered at www.isrctn.com as ISRCTN29665319 and at
eudract.ema.europa.eu as EudraCT 2009-016731-34. Am J
Clin Nutr 2016;103:1443–52.
Keywords: amino acid, lipid emulsion, parenteral nutrition, pre-
term infant, randomized controlled trial, body composition, intrahe-
patocellular lipid
INTRODUCTION
Delivering nutrition to very immature infants is challenging.
Parenteral nutrition (PN)11 requires reliable intravenous access,
pharmacist support, and clinical expertise in minimizing and
treating complications. Gastrointestinal immaturity precludes early
administration of milk volumes sufficient to support growth. In
practice, PN and milk feeds are commenced at variable intervals
after birth, with nutrient delivery increased incrementally. As
a consequence, cumulative nutrient deficits are common, and by
term the majority of very preterm infants are lighter and shorter
than healthy term-born counterparts (1). Although optimal post-
natal growth velocity is uncertain (2), the association between
slower growth and the greater likelihood of neurodevelopmental
impairment and cerebral palsy (3) has justified early PN provision.
High amino acid intakes have been advocated, with the recom-
1 This project is funded by the Efficacy and Mechanism Evaluation
(EME) Programme, an MRC and NIHR partnership (project number 08/
99/04). This is an open access article distributed under the CC-BY license
(http://creativecommons.org/licenses/by/3.0/).
2 Supplemental Figures 1–3 and Supplemental Tables 1–11 are available
from the “Online Supporting Material” link in the online posting of the
article and from the same link in the online table of contents at http://ajcn.
nutrition.org.
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mended daily intake (RDI) calculated on the basis of redressing
cumulative deficits as well as matching intrauterine growth ve-
locity (4, 5). Intravenous lipid preparations containing fish oils
have been recommended on the basis of clinical observations,
suggesting they may protect against hepatic dysfunction, a fre-
quent concomitant of PN (6). Intralipid (Fresenius Kabi) is
a widely used first-generation intravenous emulsion that contains
soybean oil, egg yolk phospholipids, and glycerin. SMOFlipid
(Fresenius Kabi), a third-generation emulsion that contains soy-
bean oil, medium-chain triglycerides, olive oil, and fish oil
(SMOF), has an altered ratio of n–6:n–3 fatty acids that is be-
lieved to be beneficial in parenteral nutrition–associated liver
impairment.
A diet with a low protein:energy ratio results in lower lean
body mass and greater adiposity (7). Thus, in the short term,
weight gain—although a widely used outcome measure—may
not be as revealing as body composition. Monitoring lipid tol-
erance is problematic because normative ranges for circulating
lipids remain inadequately defined in very preterm infants, and
relations to long-term outcomes are unclear. Whole-body MRI
can be employed to assess body composition directly and in vivo
MR spectroscopy to assess hepatic lipid noninvasively; the latter
compares favorably with the gold standard, liver biopsy, for the
quantitative assessment of hepatic steatosis (8).
We designed a clinical trial (ISRCTN29665319; EudraCT
2009-016731-34) to test the hypotheses that the immediate de-
livery of RDI (Imm-RDI) of parenteral amino acids compared
with incremental provision is more efficacious in increasing lean
(nonadipose) body mass at term, and that a mechanism of action
of 20% SMOF compared with 20% soybean-based lipid emulsion
(SO) is to reduce intrahepatocellular lipid (IHCL).
METHODS
We conducted NEON (Nutritional Evaluation and Optimisa-
tion in Neonates), a 2-by-2 factorial, double-blind, multicenter
randomized controlled trial in 4 National Health Service neonatal
units in London and southeast England. The trial was preregis-
tered and approved by the National Research Ethics Service and
Medicines and Healthcare Products Regulatory Agency. The trial
sponsor was Imperial College London. Recruitment commenced
in July 2010 and ended in July 2013, with a final follow-up in
October 2013.
Preterm infants born at ,31 wk of gestation were eligible for
inclusion. Infants with life-threatening abnormalities and those
for whom we were unable to administer trial PN within 24 h of
birth were ineligible. When possible, the trial was discussed
with parents antenatally, and written informed consent was
FIGURE 1 Consolidated Standards of Reporting Trials diagram. *Investigator withdrawal: in both cases, this occurred when the infant was transferred to
a nontrial site soon after random assignment and was therefore unable to receive the trial intervention. Imm-RDI, immediate recommended daily intake; Inc-
AA, incremental introduction of amino acid; SMOF, soybean oil, medium-chain triglycerides, olive oil, and fish oil; SO, soybean-based lipid emulsion.
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sought within 24 h of birth. The interventions were 20% SMO-
FLipid (Fresenius Kabi) and Imm-RDI of amino acids. The com-
parators were 20% Intralipid (Fresenius Kabi) and incremental
delivery of amino acids (Inc-AA). The amino acid source was
Vaminolact (Fresenius Kabi). Trial formulations were investiga-
tional medicinal products prepared by a licensed facility (Bath ASU).
Other PN components were identical across randomized groups.
Trial procedures
We randomly assigned eligible infants with the use of an
interactive voice recognition telephone system to 1 of 4 groups
(Inc-AA/SO, Inc-AA/SMOF, Imm-RDI/SO, and Imm-RDI/
SMOF) and incorporated minimization with a random element
and stratification by gestational age (23–26 or 27–31 completed
weeks), birth weight (,500, 500–1000, or.1000 g), and center.
Hospital pharmacy staff dispensed trial PN between 0900 and
1700; attending clinicians were blinded to trial allocation. For
consistency of capturing data, we defined day 1 as the period
from birth to 1700. Subsequent days of capturing data were
recorded from 1700 to 1700. The duration of day 1 was there-
fore variable and dependent on time of birth.
PN and milk intake by a nasogastric tube commenced within
24 h of birth and was guided by prespecified protocols. The
investigator manual provided instructions on managing elec-
trolyte, glucose, and lipid disturbances. Inc-AA infants received
1.7 g/kg amino acids on day 1, 2.1 g/kg on day 2, and a maximum
of 2.7 g $ kg21 $ d21 from day 3; Imm-RDI infants received 3.6
g $ kg21 $ d21 from day 1. PN was provided in an aqueous volume
of 90 mL $ kg21 $ d21 on days 1 and 2 and 120 mL $ kg21 $ d21
from day 3. Carbohydrate intake was 8.6 g $ kg21 $ d21 from day
1. An intravenous lipid was provided at 2 g $ kg21 $ d21 on day 1
and was increased to 3 g $ kg21 $ d21 from day 2. Weaning of trial
PN was commenced once an infant received milk volumes .60
mL $ kg21 $ d21.
Trial PN ceased when an infant had received and tolerated 150
mL milk $ kg21 $ d21 for$24 h. Any subsequent PN requirement
was in accordance with local practice. Nutritional intake was re-
corded prospectively on a daily basis from birth until discharge or
trial endpoint.
TABLE 1
Baseline characteristics of all randomly assigned infants1
Inc-AA/SO Inc-AA/SMOF Imm-RDI/SO Imm-RDI/SMOF
Infants, n 42 42 41 43
Male, n (%) 28 (66.7) 26 (61.9) 21 (51.2) 22 (51.2)
Gestational age, wk 27.8 6 1.92 27.5 6 2.4 28.1 6 2.1 27.8 6 2.1
Multiple birth, n (%) 6 (14.3) 6 (14.3) 9 (22.0) 15 (34.9)
Birth weight, kg 1.03 6 0.29 1.05 6 0.34 1.04 6 0.28 1.06 6 0.29
Birth length, cm 35.1 6 3.5 (31)3 34.6 6 4.2 (32) 35.1 6 3.9 (26) 35.2 6 5.2 (32)
Birth head circumference, cm 25.3 6 2.0 (41) 25.0 6 3.0 (40) 25.3 6 1.9 (37) 25.6 6 2.9 (39)
Birth weight,4 z score 20.2 6 1.0 (42) 0.1 6 1.0 (41) 20.2 6 1.0 (41) 0 6 0.9 (43)
Birth length,4 z score 21.0 6 1.0 (30) 20.9 6 1.2 (24) 21.1 6 1.0 (25) 20.8 6 1.5 (29)
Birth head circumference,4 z score 20.5 6 0.9 (41) 20.3 6 1.0 (39) 20.7 6 0.9 (37) 20.2 6 1.6 (41)
Characteristics of mother
Age, y 32.9 6 5.3 (42) 31.3 6 7.7 (42) 32.9 6 6.3 (40) 32.5 6 6.6 (43)
Weight,5 kg 66.4 6 13.3 (34) 65.9 6 11.4 (25) 64.9 6 13.0 (30) 68.5 6 15.2 (33)
Height,5 cm 161.9 6 7.8 (33) 164.9 6 7.7 (27) 161.3 6 9.2 (27) 164.5 6 8.6 (32)
Ethnicity, n (%)
White 16 (38.1) 19 (45.2) 21 (51.2) 21 (48.8)
Asian 14 (33.3) 7 (16.7) 12 (29.3) 12 (27.9)
Black 6 (14.3) 13 (31.0) 6 (14.6) 6 (14.0)
Mixed 2 (4.8) 2 (4.8) 1 (2.4) 2 (4.7)
Other 3 (7.1) 0 (0) 1 (2.4) 2 (4.7)
Missing 1 (2.4) 1 (2.4) 0 (0) 0 (0)
Mode of delivery, n (%)
Vaginal 8 (19.1) 18 (42.9) 16 (39.0) 17 (39.5)
Elective cesarean 7 (16.7) 3 (7.1) 4 (9.8) 2 (4.7)
Emergency cesarean 27 (64.3) 21 (50.0) 21 (51.2) 24 (55.8)
Antenatal steroids, n (%)
Yes 30 (71.4) 34 (81.0) 32 (78.1) 35 (81.4)
No 7 (16.7) 6 (14.3) 7 (17.1) 4 (9.3)
Unknown 5 (11.9) 2 (4.8) 2 (4.9) 4 (9.3)
Time from birth to starting parenteral nutrition,6 h 18.4 (12.3, 22.7) 19.5 (13.6, 22.8) 20.4 (12.6, 23.6) 17.7 (13.0, 22.4)
1Imm-RDI, immediate recommended daily intake; Inc-AA, incremental introduction of amino acid; SMOF, soybean oil, medium-chain triglycerides,
olive oil, and fish oil; SO, soybean-based lipid emulsion.
2Mean 6 SD (all such values).
3Mean 6 SD; n in parentheses (all such values).
4Data are from reference 15.
5Measured at booking.
6Values are medians; IQRs in parentheses; n = 42, 41, 40, and 43 for Inc-AA/SO, Inc-AA/SMOF, Imm-RDI/SO, and Imm-RDI/SMOF groups,
respectively.
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Outcomes
Primary outcomes were nonadipose mass for the amino acid
intervention and IHCL for the lipid intervention. Secondary
outcomes were total adiposity, adipose tissue depots, insulin
sensitivity (quantitative insulin sensitivity check index) (9), total
and regional brain volumes, weight, head circumference, and
length. We evaluated prespecified safety measures (serum lipids,
cholesterol, creatinine, urea, bilirubin, liver function tests, blood
glucose, and base deficit) from routine clinical tests. We recorded
serious adverse events, including sepsis and death.
MRI and MR spectroscopy
We evaluated primary outcomes between 37 and 44 wk
postmenstrual age. We carried out whole-body MRI and in vivo
hepatic 1H MR spectroscopy at 1.5T during natural sleep
without sedation. We obtained serial axial images (5-mm slice
and interslice thickness) to quantify total adipose tissue volume
as the sum of 6 discrete depots (Supplemental Figure 1) as
previously described (10). We estimated nonadipose or lean
mass as the difference between whole-body and adipose mass
with the following formula: [body weight (g) - [adipose tissue
volume (cm3) 3 0.9]]. Image analysis with the use of Slice-O-
Matic (version 4.2; Tomovision) was undertaken independently
by the Vardis Group and was blinded to participant identity and
group allocation. We acquired MR spectra from the right lobe of
the liver with the use of a point-resolved sequence (repetition
time, 1500 ms; echo time, 135 ms) without water saturation and
with 128 signal averages. Spectra were analyzed with the use of
the advanced method for accurate, robust, and efficient spectral
fitting algorithm in the jMRUI software package (version 1.3;
MRUI consortium; www.jmrui.eu/) by a single investigator who
was blinded to allocation (11, 12). IHCL was expressed as lipid:
water peaks.
Trial oversight
We established a trial steering committee to oversee study
conduct and an independent data monitoring and ethics com-
mittee to review safety reports and interim analyses. The trial was
managed by the Imperial College London Clinical Trials Unit.
We used the InForm Integrated Trial Management system that
included a web-based electronic case record form, built-in val-
idation rules, calculation of nutrient intakes, serious and specific
adverse event reporting, and a complete audit trail. Participating
sites received initiation, routine monitoring, and closeout visits.
Sample size
We based the sample size on our estimate that 64 infants in
each pairwise group (Imm-RDI compared with Inc-AA) would
provide 80% power (2-sided; 5% significance) to detect a 200-g
difference in nonadipose mass assuming an SD of 400 g. This
represents half the difference in the nonadipose mass we iden-
tified between very preterm and term infants in a prior
FIGURE 2 Mean daily protein, daily carbohydrate, daily fat, and daily energy intakes from all sources across the 4 groups during the first 2 postnatal
weeks. Imm-RDI, immediate recommended daily intake; Inc-AA, incremental introduction of amino acid; SMOF, soybean oil, medium-chain triglycerides,
olive oil, and fish oil; SO, soybean-based lipid emulsion.
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experimental cohort (13). We have previously reported IHCL
values for very preterm infants at term (mean 6 SD lipid:water
ratio: 1.75 6 1.85; range: 0.14–7.72) (14). Because the distri-
bution is positively skewed, we used a loge transformation to
provide a mean 6 SD IHCL of 0.121 6 1.052 and range be-
tween 21.97 and 2.04. We calculated that 64 infants in each
pairwise group would provide 80% power (5% significance) to
detect a difference in a mean IHCL of 0.53 on the logarithmic
scale. Back-transforming to the original scale of measurement,
this is equivalent to a 40% decrease in IHCL in the intervention
group. We assumed there would be no interaction between the
interventions. Allowing for 10% mortality and #10% dropout
(including infants still in the hospital at 44 wk postmenstrual age),
we aimed to recruit 160 infants or until 64 infants in each pairwise
group had undergone MRI and MRS, a total of 128 scans.
Statistical analysis
We used a modified intention-to-treat analysis because we
anticipated we would be unable to obtain primary outcome
measures in all infants. For the amino acid and lipid interventions,
we used multiple regression with nonadipose mass (grams) or
IHCL (natural logarithmic scale) as the dependent variables and
the amino acid group (Inc-AA or Imm-RDI), lipid group (SO or
SMOF), stratifying variables (gestational age, birth weight, and
center), sex, and age at assessment as the independent variables.
We added an interaction term to assess whether the effect of
amino acid regimen is influenced by lipid type. In a planned
secondary analysis, we incorporated measures of illness severity
and nutritional intake in the regression models to investigate their
role as potential effect modifiers. We performed all analyses with
the use of Stata version 13 (StataCorp LP).
RESULTS
Baseline characteristics
We randomly assigned 168 infants, of whom 133 received
primary outcome assessments (Figure 1). Baseline characteris-
tics were well balanced (Table 1, Supplemental Table 1). For
ease of comparison between enteral and parenteral intakes, we
expressed parenteral amino acid intake as protein (1 g amino
acids = 0.89 g protein). Trial PN protein intake was higher in the
Imm-RDI arms in the first 2 wk (Figure 2, Supplemental
Tables 2 and 3) , demonstrating that target intakes were reached;
carbohydrate, lipid, and energy intakes were similar across the 4
groups (Figure 2). Cumulative PN (trial and nontrial) and enteral
protein intakes between birth and 34 wk postmenstrual age are
provided in Supplemental Tables 2 and 3 and 4–6.
The median (IQR) number of days to achieve a milk intake of
150 mL $ kg21 $ d21 for 24 h was similar across the 4 groups
(Imm-RDI/SO 11 d: IQR, 10–14 d; Imm-RDI/SMOF 13 d: IQR,
10–18 d; Inc-AA/SO 12 d: IQR: 9–18 d; and Inc-AA/SMOF 12
d: 9–16 d) (Supplemental Tables 7 and 8). Macronutrient and
FIGURE 3 Mean daily protein, daily carbohydrate, daily fat, and daily energy intakes from all sources across the 4 groups after the first 2 postnatal
weeks. Imm-RDI, immediate recommended daily intake; Inc-AA, incremental introduction of amino acid; SMOF, soybean oil, medium-chain triglycerides,
olive oil, and fish oil; SO, soybean-based lipid emulsion.
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energy intake from milk and PN from the end of the second
week onward did not differ between groups (Figure 3).
Primary outcomes
There was no significant difference between the Imm-RDI and
Inc-AA groups in nonadipose mass at term [adjusted mean
difference: 1.0 g (95% CI: 2108, 111 g); P = 0.98] or between
the SMOF and SO groups in IHCL [adjusted mean SMOF:SO
ratio: 1.1 (95% CI: 0.8, 1.6); P = 0.58] (Table 2). There was
a significant interaction (P = 0.05) between the 2 interventions
for nonadipose mass (Supplemental Figure 2 and Table 2).
There were no significant interactions between group differences
for either primary outcome measure after adjustment for addi-
tional confounders (Table 3).
Secondary outcomes
Head circumference at term was smaller in the Imm-RDI
group than in the Inc-AA groups [adjusted mean difference:
20.8 cm (95% CI: 21.5, 20.1 cm); P = 0.02] (Table 2). There
were no significant differences in any other prespecified sec-
ondary outcomes (Table 2). Weight gain over the study period
was similar across groups (Supplemental Figure 3). Additional
nutritional information, sepsis incidence, and length of hospital
stay are shown in Supplemental Tables 7 and 8.
Safety
There were significantly more infants in Imm-RDI groups with
blood urea nitrogen concentrations .7 mmol/L (Imm-RDI/SO,
70.7%; Imm-RDI/SMOF, 79.1%; Inc-AA/SO, 50%; Inc-AA/
SMOF, 47.6%; P , 0.01) and with concentrations .10 mmol/L
(Imm-RDI/SO, 43.9%; Imm-RDI/SMOF, 53.5%; Inc-AA/SO,
14.3%; Inc-AA/SMOF, 21.4%; P , 0.01) (Supplemental Table
9). There were no significant differences in the proportion of
infants with any other abnormal biochemical indexes, including
incidence of conjugated hyperbilirubinemia (Supplemental
Tables 9 and 10). Serious adverse events are summarized in
Supplemental Table 11.
DISCUSSION
We found that PN providing an Imm-RDI of amino acids did
not benefit body composition or affect growth at term in very
preterm infants born at,31 wk of gestation. We did not identify
a significant difference in IHCL between infants receiving SO
and SMOF. Calls for aggressive nutritional regimens involving
earlier PN initiation and high protein intakes (4, 5) are reflected
in international consensus guidelines that advocate amino acid
intakes #4 g $ kg21 $ d21 (17). Observational reports have led
to the hope that new fish oil–containing lipid formulations might
reduce the high prevalence of PN-associated liver dysfunction
(18). Our results do not support these recommendations.
Key strengths of NEONwere excellent trial protocol adherence,
including the introduction of milk within 24 h of birth and
a prespecified approach to the management of electrolyte distur-
bances despite clinician blinding to group allocation. The need for
central venous access can limit early commencement; hence, the
composition of trial PN permitted delivery by the peripheral vein.
Both gestational age strata (23–26 and 27–31 wk) were broadly
equal across groups, making the trial results applicable to the
most immature infants. NEON was adequately powered because
the CIs for the mean differences in nonadipose mass and the
SMOF:SO IHCL ratio, respectively, excluded the prespecified
difference of 200 g and decrease of 40%. Because we know of no
biological reason for lipid type to influence the quantity of non-
adipose tissue, we consider it likely that the between-intervention
interaction we detected resulted from chance.
We acknowledge limitations. Our study was carried out in 4
neonatal units, with primary outcome assessments at the lead
university hospital. We considered it unethical to transfer an
infant between hospitals for research purposes so we were unable
to obtain primary outcome measures for infants recruited in
nonlead centers who remained inpatients at term. However,
primary outcome measurements were available for 133 infants
because the trial design allowed for recruitment to continue until
128 (based on sample size calculation) measurements were
available. Recruitment during the weekend was not feasible in
all centers because of the lack of availability of pharmacy staff
trained in clinical trial procedures; thus, a number of eligible
infants were unable to participate. We were able to assess brain
TABLE 3
Primary outcome results after further adjustments for level of care and nutritional intake1
Adjusted mean difference (95% CI)2
Interaction
Adjusted mean difference (95% CI)3
InteractionImm-RDI/Inc-AA SMOF/SO Imm-RDI/Inc-AA SMOF/SO
Nonadipose mass, g 1 (2108, 111);
P = 0.98
241 (2150, 68);
P = 0.46
216 (0, 432);
P = 0.05
244 (2226, 139);
n = 130;
P = 0.64
214 (2114, 86);
n = 130;
P = 0.78
184 (222, 390);
P = 0.08
IHCL4 0.7 (0.5, 1.1);
n = 132;
P = 0.11
1.1 (0.8, 1.6);
n = 132;
P = 0.58
0.8 (0.4, 1.7);
n = 132;
P = 0.53
0.81 (0.37, 1.80);
n = 129;
P = 0.61
0.89 (0.61, 1.31);
n = 129;
P = 0.57
0.86 (0.39, 1.92);
n = 129;
P = 0.71
1IHCL, intrahepatocellular lipid; Imm-RDI, immediate recommended daily intake; Inc-AA, incremental introduction of amino acid; SMOF, soybean oil,
medium-chain triglycerides, olive oil, and fish oil; SO, soybean-based lipid emulsion.
2Adjusted for age at scan, sex, gestational age, birth weight, and center.
3Adjusted for age at scan, sex, gestational age, birth weight z score (15), center, level of care [percentage of time spent receiving intensive and high-
dependency care between birth and assessment (16)], and nutritional intake.
4Log transformation was used in the regression model; the results were transformed back from the logarithmic scale and presented as the ratio
intervention:control.
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volumes in only one-third of participants because we carried out
MRI investigations without sedation (19), obtaining primary
outcome measures first and proceeding to brain imaging only if
the infant remained asleep.
PN is a high-cost, widely used neonatal intensive care inter-
vention, yet to our knowledge there have been few previous
randomized controlled trials and none that have evaluated the
effects on body composition (20). We achieved a clear difference
in amino acid intake between Imm-RDI and Inc-AA groups. The
possible reasons why this did not translate into a difference in
body composition or weight at termmerit consideration. First, the
Imm-RDI groups had a significantly higher incidence of elevated
blood urea concentrations. This suggests that increased delivery
above a threshold results in increased amino acid oxidation with
no improvement in nitrogen retention or growth, as suggested
previously (6, 21, 22). We consider it unlikely that the impaired
utilization of amino acids was attributable to inadequate non-
protein energy because nonprotein energy did not differ between
the groups; however, it is plausible that the amino acid solutions
in current use may not be optimal for preterm infants. Second, trial
interventions may have resulted in a short-term difference in body
composition that was attenuated when infants transitioned to self-
regulated consumption. Embleton et al. (23) showed that infants
that consumed a higher protein formula by a nasogastric tube
achieved an increase in lean body mass that did not persist after
a period of self-regulated consumption by bottle.
More than a decade ago, we found lean body mass at term to be
almost 500 g lower in very preterm than in healthy term infants
(13), which is in marked contrast to a recent study (24) and in
NEON, in which the difference was only w200 g. The in-
cremental regimen delivered a maximum PN amino acid intake
of 2.7 g $ kg21 $ d21 (equivalent to 2.4 g protein $ kg21 $ d21)
because this was considered a standard of care in the United
Kingdom at the time. However, total protein intakes were higher
because milk feeds were commenced within 24 h of birth. Early
commencement of milk feeds together with PN, as delivered in
NEON, counter the assumption that very preterm infants in-
evitably accrue substantial postnatal deficits and hence require
protein intakes .4.5 g $ kg21 $ d21 (17). We used IHCL as
a mechanistic marker because concentrations at term correlate
with early lipid intake (25) and are higher in very preterm in-
fants than in full-term infants (14) and young adults (26). We
also monitored liver function with the use of conventional bio-
chemical markers and identified no between-group differences.
Overall, our data support the conclusion of a systematic review
and meta-analysis that fish oil–based lipid emulsions do not
prevent PN-associated cholestasis (18), although we do not
preclude the possibility that other formulations may be benefi-
cial, including those with higher fish oil content.
We noted a smaller head circumference at term in infants
receiving the higher amino acid intake. This observation is at
odds with the Standardised, Concentrated Additional Macro-
nutrients, Parenteral Nutrition in very preterm infants study. in
which very preterm neonates randomly assigned to receive higher
PN from birth had a larger head circumference at 28 d (27). Of
note is that although the Standardised, Concentrated Additional
Macronutrients, Parenteral Nutrition in very preterm infants
study. aimed to deliver high amounts of PN, randomization
occurred up to 120 h of age (compared with 24 h in NEON);
hence, infants received a lower mean energy and amino acid
intake over the first 3 postnatal days than NEON infants. NEON
was not powered to detect a difference in head circumference, but
our observation is a concern because the possibility of adverse
effects from higher PN intakes has been raised previously. A
study that compared 3.5-g/kg amino acids and 2-g/kg lipids from
the first postnatal day against an incremental regimen was ter-
minated early because of increased sepsis in the former group
(28). Choudri et al. (29) showed smaller brain growth and
compromised neurodevelopment despite equivalent weight gain
in preterm piglets receiving total parenteral compared with total
enteral nutrition. Blanco et al. (30) found that infants receiving an
immediate parenteral amino acid intake of 2–4 g $ kg21 $ d21
compared with a group that was randomly assigned to receive
a lower intake had a lower mean mental development index at
18 mo and lower mean z scores for weight, length, and head
circumference. We reassuringly identified no between-group
differences in brain volume in NEON.
We conclude that commencing an Inc-AA regimen that pro-
vides a maximum of 2.7 g $ kg21 $ d21 together with introducing
milk feeds within 24 h of birth does not seem to be detrimental
to body composition and may also be safer compared with the
immediate provision of an amino acid intake of 3.6 g $ kg21 $
d21. We also conclude that SMOF does not reduce intrahepatic
lipid accumulation. We found that a standardized PN regimen
was well accepted by clinicians and well tolerated by infants.
We intend to evaluate growth and cognitive, developmental, and
other functional outcomes in childhood. Optimal amino acid
intakes and intravenous lipid formulations for extremely preterm
infants remain to be established.
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